Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

(2021) Michael S Hofman et al.   LANCET

Clinical investigation of neuroendocrine differentiation in prostate cancer.

(2020) Tatsuya Shimomura et al.   JOURNAL OF CLINICAL ONCOLOGY

Neuroendocrine and Aggressive-Variant Prostate Cancer

(2020) Nicholas Spetsieris et al.   Cancers

Lu177‐ PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution

(2019) Rhiannon McBean et al.   Journal of Medical Imaging and Radiation Oncology

Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play

(2019) Patel et al.   Cancers

Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for FDG imaging of PSMA-suppressed tumors

(2019) Martin K. Bakht et al.   JOURNAL OF NUCLEAR MEDICINE

Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223

(2019) Matteo Bauckneht et al.   Cancers

Adenocarcinoma Prostate With Neuroendocrine Differentiation

(2018) Girish Kumar Parida et al.   CLINICAL NUCLEAR MEDICINE

Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer

(2018) Stephen Yiu Chuen Choi et al.   Cancer Medicine

18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor

(2018) Emine Acar et al.   CLINICAL NUCLEAR MEDICINE

Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer

(2017) Min Zou et al.   Cancer Discovery

68Ga-DOTATOC and 68Ga-PSMA PET/CT Unmasked a Case of Prostate Cancer With Neuroendocrine Differentiation

(2016) Sirong Chen et al.   CLINICAL NUCLEAR MEDICINE

The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma

(2016) W. Li et al.   MOLECULAR CANCER RESEARCH

Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer

(2013) H. Jadvar et al.   JOURNAL OF NUCLEAR MEDICINE

Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study

(2011) Sundeep Deorah et al.   BJU INTERNATIONAL

Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer

(2009) Ganesh S. Palapattu et al.   PROSTATE

FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate

(2008) Yiyan Liu   World Journal of Surgical Oncology